Genomic Assay Predicts Probability of Heart Transplant Rejection
By LabMedica International staff writers Posted on 05 Mar 2014 |
Results obtained over time by a gene expression assay used to monitor heart transplant patients for signs of rejection may be able to predict the likelihood of rejection in the future.
The AlloMap Molecular Expression Test, which is manufactured and performed by the biomedical company XDx (Brisbane, CA, USA), is an in vitro diagnostic multivariate index assay (IVDMIA) testing service. The assay, which is performed in a single laboratory, assesses the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing may be used to evaluate transplant patients aged 15 years or older from at least two months after the transplant. It is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
AlloMap, which measures the expression levels of 11 rejection-related genes from a patient's blood sample, received clearance from the [US] Food and Drug Administration (FDA) in 2008 and it is now routinely used by a majority of American heart transplant centers to monitor low-risk patients during follow-up care, resulting in a substantial reduction in the number of heart-muscle biopsies.
Investigators at the University of California, Los Angeles (USA) recently evaluated data obtained by a study of 600 heart transplant recipients who had been monitored by routine biopsy or with the AlloMap test. They found that the variability of a heart recipient's gene expression profiling test scores over time could provide prognostic utility. This information was independent of the probability of acute cellular rejection at the time of testing.
"The AlloMap was the first FDA-cleared test allowing transplant centers to rule out rejection at the time of the visit," said first author Dr. Mario Deng, professor of medicine at the University of California, Los Angeles. "But until now, it has never been used to predict future events. For the first time, we can use genomic testing over multiple patient visits to go beyond intuition to understand not just how patients are doing now but how they are likely to be a few months from now. It is another step toward personalized medicine."
The study was published in the January 31, 2014, online edition of the journal Transplantation.
Related Links:
XDx
University of California, Los Angeles
The AlloMap Molecular Expression Test, which is manufactured and performed by the biomedical company XDx (Brisbane, CA, USA), is an in vitro diagnostic multivariate index assay (IVDMIA) testing service. The assay, which is performed in a single laboratory, assesses the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing may be used to evaluate transplant patients aged 15 years or older from at least two months after the transplant. It is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
AlloMap, which measures the expression levels of 11 rejection-related genes from a patient's blood sample, received clearance from the [US] Food and Drug Administration (FDA) in 2008 and it is now routinely used by a majority of American heart transplant centers to monitor low-risk patients during follow-up care, resulting in a substantial reduction in the number of heart-muscle biopsies.
Investigators at the University of California, Los Angeles (USA) recently evaluated data obtained by a study of 600 heart transplant recipients who had been monitored by routine biopsy or with the AlloMap test. They found that the variability of a heart recipient's gene expression profiling test scores over time could provide prognostic utility. This information was independent of the probability of acute cellular rejection at the time of testing.
"The AlloMap was the first FDA-cleared test allowing transplant centers to rule out rejection at the time of the visit," said first author Dr. Mario Deng, professor of medicine at the University of California, Los Angeles. "But until now, it has never been used to predict future events. For the first time, we can use genomic testing over multiple patient visits to go beyond intuition to understand not just how patients are doing now but how they are likely to be a few months from now. It is another step toward personalized medicine."
The study was published in the January 31, 2014, online edition of the journal Transplantation.
Related Links:
XDx
University of California, Los Angeles
Latest Molecular Diagnostics News
- RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia
- New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis
- Injury Molecular Fingerprint Enables Real-Time Diagnostics for On-Site Treatment
- Blood Test Could Predict Likelihood of Breast Cancer Spreading to The Bone
- New Infectious Disease Analytics Platform Speeds Up Clinical Decision-Making at POC
- Genetic Test Could Predict Poor Outcomes in Lung Transplant Patients
- Breakthrough Blood Test Enables Early Pancreatic Cancer Detection
- Genomic Testing in NICU Reduces Missed Diagnoses
- New Genetic Test Improves Diabetes Prediction and Classification
- New Blood Test for Leukemia Risk Detection Could Replace Bone Marrow Sampling
- Blood Test Detects Preeclampsia Risk Months Before Symptoms Appear
- mNGS CSF Test Outperforms Traditional Microbiological Testing for Infectious Diseases
- Point-Of-Care Test to Transform Early-Stage Cervical Cancer Diagnosis
- PET/ctDNA-Guided Approach Helps Determine Lymphoma Treatment
- Next-Generation 'Agnostic Diagnostics' to Detect Respiratory Viruses at POC
- First-Ever Test of Cure for Chagas Disease Determines Treatment Effectiveness
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Performs Virtual Tissue Staining at Super-Resolution
Conventional histopathology, essential for diagnosing various diseases, typically involves chemically staining tissue samples to reveal cellular structures under a microscope. This process, known as “histochemical... Read more
AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read moreTechnology
view channel
Inexpensive DNA Coated Electrode Paves Way for Disposable Diagnostics
Many people around the world still lack access to affordable, easy-to-use diagnostics for diseases like cancer, HIV, and influenza. Conventional sensors, while accurate, often rely on expensive equipment... Read more
New Miniature Device to Transform Testing of Blood Cancer Treatments
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for blood cancers like leukemia, offering hope to patients when other treatments fail. However, despite its promise,... Read moreIndustry
view channel
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more